Skip to main content

Sign up for our newsletter.

Quality journalism. Progressive values. Direct to your inbox.

If you’ve been waiting for the right time to support our work—that time is now.

Our mission is simple: To inform. To inspire. To ignite change for the common good.

But without the support of our readers, this model does not work and we simply won’t survive. It’s that simple.
We must meet our Mid-Year Campaign goal but we need you now.

Please, support independent journalism today.

Join the small group of generous readers who donate, keeping Common Dreams free for millions of people each year. Without your help, we won’t survive.

Bernie Sanders

Sen. Bernie Sanders (I-Vt.) speaks during a pen and pad news conference on Capitol Hill on October 8, 2021. (Photo: Anna Moneymaker/Getty Images)

Sanders Calls on Biden to Slash 'Outrageous' Medicare Premium Hike

"It would be absolutely unacceptable to force 57 million senior citizens to pay $11.50 more a month in Medicare premiums" due to Big Pharma's greed, the Vermont senator said.

Jake Johnson

Sen. Bernie Sanders on Friday implored President Joe Biden to step in and prevent a looming Medicare premium hike stemming from the Food and Drug Administration's widely condemned approval of an expensive—and possibly ineffective—Alzheimer's drug.

In a letter to the president, Sanders (I-Vt.) noted that the pharmaceutical company Biogen has placed a $56,000-per-year price tag on Aduhelm, a treatment that the FDA approved in June despite experts' concerns about the dearth of evidence showing it actually works to slow Alzheimer's-induced cognitive decline.

"With Democrats in control of the White House, the House, and the Senate, we cannot let that happen."

"Incredibly and immorally, Biogen... has set the price of this Alzheimer's drug at $56,000 even though the Institute for Clinical and Economic Review, an independent non-profit organization, has estimated that the maximum price of this drug should be no higher than $3,000-$8,400," the Vermont senator wrote. "This is a perfect example of why Medicare should be negotiating drug prices with the pharmaceutical industry."

Last month, as Common Dreams reported, the Centers for Medicare and Medicaid Services (CMS) announced that monthly Medicare Part B premiums would be increased to $170.10 in 2022, up from the current level of $148.50.

CMS officials attributed around half of the planned hike—which would be one of the largest in Medicare's history—to "additional contingency reserves due to the uncertainty regarding the potential use of the Alzheimer's drug, Aduhelm™, by people with Medicare."

Without the Aduhelm-related increase—which Sanders is pushing Biden to block—the monthly Medicare premium for 2022 would be around $159.

Medicare officials are still in the process of deciding whether the program will cover the exorbitantly priced drug, which the Department of Veterans Affairs decided not to include on its national formulary, citing "lack of evidence of a robust and meaningful clinical benefit."

Sanders called the planned premium increase "outrageous" and argued that "it would be absolutely unacceptable to force 57 million senior citizens to pay $11.50 more a month in Medicare premiums due to Biogen's greed and thirst for massive profits for a drug that has not been proven to be effective by the scientific community."

"The notion that one pharmaceutical company can raise the price of one drug so much that it could negatively impact 57 million senior citizens and the future of Medicare is beyond absurd," he continued. "With Democrats in control of the White House, the House, and the Senate, we cannot let that happen."

Specifically, Sanders called on Biden to direct the U.S. Department of Health and Human Services to "immediately prevent the $11.50 a month increase in Medicare Part B premiums associated with Aduhelm from going into effect next year."

The senator also urged Biden to instruct CMS to delay its approval of Aduhelm and "take executive action to reinstate and expand the reasonable pricing clause that was established in 1989 by the National Institutes of Health requiring drug makers to charge reasonable prices for prescription drugs and treatments that receive federal funding."

Public health campaigners have been warning for months that the FDA's approval of Aduhelm—which led several agency advisers to resign in protest—could spell disaster for Medicare.

Dr. Michael Carome, director of Public Citizen's Health Research Group, said in a November statement that "all Part B Medicare beneficiaries soon will be forced to bear significant financial burden as a direct result of the FDA's reckless decision to approve [Aduhelm], a drug that has not been proven to provide any clinically meaningful benefit to Alzheimer's."

"To protect the many Medicare beneficiaries who cannot afford the unacceptable 15% jump in Part B premiums," Carome added, "CMS must promptly announce that it will exclude [Aduhelm] from coverage under the Medicare program until there is definitive evidence that the drug provides substantial... cognitive benefit to Alzheimer’s disease patients."


Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.

"I'm sure this will be all over the corporate media, right?"
That’s what one longtime Common Dreams reader said yesterday after the newsroom reported on new research showing how corporate price gouging surged to a nearly 70-year high in 2021. While major broadcasters, newspapers, and other outlets continue to carry water for their corporate advertisers when they report on issues like inflation, economic inequality, and the climate emergency, our independence empowers us to provide you stories and perspectives that powerful interests don’t want you to have. But this independence is only possible because of support from readers like you. You make the difference. If our support dries up, so will we. Our crucial Mid-Year Campaign is now underway and we are in emergency mode to make sure we raise the necessary funds so that every day we can bring you the stories that corporate, for-profit outlets ignore and neglect. Please, if you can, support Common Dreams today.

 

'We Need Action': Biden, Democrats Urged to Protect Abortion Access in Post-Roe US

"The Supreme Court doesn't get the final say on abortion," Sens. Elizabeth Warren and Tina Smith wrote in a new op-ed.

Kenny Stancil ·


Motorist 'Tried to Murder' Abortion Rights Advocates at Iowa Protest, Witnesses Say

Although one witness said the driver went "out of his way" to hit pro-choice protestors in the street, Cedar Rapids police declined to make an arrest.

Kenny Stancil ·


'A Hate Crime': Oslo Pride Parade Canceled After Deadly Shooting at Gay Bar

A 42-year-old gunman has been charged with terrorism following what Norway's prime minister called a "terrible and deeply shocking attack on innocent people."

Kenny Stancil ·


'We WILL Fight Back': Outrage, Resolve as Protests Erupt Against SCOTUS Abortion Ruling

Demonstrators took to the streets Friday to defiantly denounce the Supreme Court's right-wing supermajority after it rescinded a constitutional right for the first time in U.S. history.

Brett Wilkins ·


80+ US Prosecutors Vow Not to Be Part of Criminalizing Abortion Care

"Criminalizing and prosecuting individuals who seek or provide abortion care makes a mockery of justice," says a joint statement signed by 84 elected attorneys. "Prosecutors should not be part of that."

Kenny Stancil ·

Common Dreams Logo